Surprising number of businesses selling unapproved stem cell ‘treatments’ in the US

At least 351 companies across the United States are marketing unapproved stem cell procedures at 570 individual clinics. Such businesses advertise ‘stem cell’ interventions for orthopedic injuries, neurological disorders, cardiac diseases, immunological conditions, pulmonary disorders, injured spinal cords, and cosmetic indications. A stem cell researcher now presents an analysis of US businesses engaged in ‘direct-to-consumer’ marketing of these procedures.